more_reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Canadian Biotech Targets Massive Cell Technology Gains

Research Report
  ()
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) recently announced a partnership with Eledon Pharmaceuticals Inc. (ELDN:NASDAQ) to explore the utility of Eledon's clinical-stage anti-CD40L monoclonal antibody tegoprubart/AT-1501 for conferring sustainable immune evasion of pancreatic islets deployed into Sernova's Cell Pouch device. Read on to see why one Leede Financial Inc. analyst rates this stock as a Speculative Buy.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Still a Buy Despite Manufacturing Setbacks

Research Report
  ()
While it received a lower price target due to manufacturing setbacks, Jasper Therapeutics Inc. (JSPR:NASDAQ) is still a Buy, according to an H.C. Wainwright & Co. research note.
Tags: Biotechnology / Pharmaceuticals

Vaccine Co. Secures European Regulatory Breakthrough Potential

Research Report
  ()
GeoVax Labs Inc. (GOVX:NASDAQ) recently raised US$6 million, projected to find operations through the last quarter of 2025, according to a ROTH Capital Markets research note. The company also received highly favorable guidance for GEO-MVA, its prophylactic vaccine for Mpox and smallpox from The European Medicines Agency.
Tags: Biotechnology / Pharmaceuticals

Analyst Has Confidence in Biotech's Path

Research Report
  ()
Vertex Pharmaceuticals Inc.'s (VRTX:NASDAQ) updated data is "a strong positive read-through for Sernova and help de-risk the broader field of cell-based therapies in T1D," according to an H.C. Wainwright & Co. research note.
Tags: Biotechnology / Pharmaceuticals

California Biotech's Trial Shows Encouraging Results

Research Report
  ()
Kura Oncology Inc.'s (KURA:NASDAQ) KOMET-007 trial results, supporting ziftomenib's benefit-risk profile for first-line acute myeloid leukemia, were encouraging, according to an H.C. Wainwright & Co. research note.
Tags: Biotechnology / Pharmaceuticals

Q1/25 Financials of Cancer Drug Developer Released

Research Report
  ()
Rakovina Therapeutics Inc.'s (RKV:TSX.V) CA$4 million equity offering is nearing completion, noted a Leede Financial Inc. report.
Tags: Biotechnology / Pharmaceuticals

New RA Drug Shown to Work, Be Safe

Research Report
  ()
"Efficacy at six months represented a 'best case' scenario, in our view," and "safety was very favorable," noted a Wedbush report.
Tags: Biotechnology / Pharmaceuticals

Analyst Likes Co. Developing Immuno-oncology Drugs

Research Report
  ()
There are multiple reasons to be bullish on this undervalued stock with significant potential upside, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Co.'s New Cancer Drug Shows Promise

Research Report
  ()
Preclinical results support this asset's dual mechanism of action in abating cancer drug resistance and reversing cancer-induced immune suppression, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Reaches MS Clinical Program Milestones

Research Report
  ()
These include release of additional Phase 2 trial data and completion of enrollment for two separate Phase 3 studies, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Phase 2b Trial Data on Treatment for Inflammation Due Soon

Research Report
  ()
These results are expected to be favorable based on positive results of a recent interim study, noted a ROTH Capital Partners report.
Tags: Biotechnology / Pharmaceuticals

Data Readout Positive from Trial of New Schizophrenia Drug

Research Report
  ()
This new dopamine-serotonin system modulator showed sustained efficacy over 52 weeks and a favorable tolerability and safety profile, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Co. Prepares to Roll Out Wound Irrigating Solution

Research Report
  ()
BioLargo Inc.'s (BLGO:OTCQX) subsidiary has all the necessary partners in place and working on integrating the various systems, such as purchasing, accounting, forecasting, logistics and quality assurance, noted an Oak Ridge Financial report.
Tags: Biotechnology / Pharmaceuticals

Biopharma Receives PDUFA Date for Lead Program

Research Report
  ()
This is a critical milestone for the company and significant for the space given the lack of approved therapies, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Biopharma Shares Efficacy Data at AUA Meeting

Research Report
  ()
These results and input from key opinion leaders boost "our enthusiasm for this candidate's prospects as a treatment for non-muscle, invasive bladder cancer, noted an Oppenheimer report.
Tags: Biotechnology / Pharmaceuticals

New Cell Treatment for Bladder Cancer Shows Promise

Research Report
  ()
This investigative therapy is "uniquely positioned to occupy a distinct segment" within the evolving and crowded space, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Biotech Discovers Revolutionary Immunotherapy in Houston

Research Report
  ()
Coya Therapeutics Inc. (COYA:NASDAQ) recently reported a statistically significant Treg improvement in FTD patients with its dual-action immunotherapy, showing promising neuroprotection, according to a D. Boral research note.
Tags: Biotechnology / Pharmaceuticals

Analyst Reveals Undervalued Pharmaceutical Gem in Canada

Research Report
  ()
In a recent research note from Leede Financial Inc. analyst Dr. Douglas Loe said Theratechnologies Inc. (TH:TSX; THTX:NASDAQ) has long term potential.
Tags: Biotechnology / Pharmaceuticals

New Drug for Early AD Shown to be Efficacious, Safe

Research Report
  ()
Trial participants exhibited improvements in cognitive function and activities of daily living, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Rest of 2025 Rich With Catalysts for Immunotherapy Co.

Research Report
  ()
These anticipated events will advance the oncology firm's lead candidate, for lung-only metastatic osteosarcoma, toward commercialization, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Four-Year Data on New Drug for Early AD Positive

Research Report
  ()
Long-term treatment with this small molecule seems feasible given its safety and tolerability profile, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Share Price Appreciation of Biotech Due Over Next Six Months

Research Report
  ()
Given its robust pipeline, numerous milestones for this Outperform-rated company are slated to occur in the near-term, noted a Wedbush report.
Tags: Biotechnology / Pharmaceuticals

New Therapy for AATD Could be Best in Class

Research Report
  ()
Updated trial data show it to be safe and efficacious and have a dual mechanism of action, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Has Promising AI-Accelerated Pipeline

Research Report
  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) recently gained analyst coverage from First Berlin Equity Research. Read on to see why this company rates the stock a Buy.
Tags: Biotechnology / Pharmaceuticals

Ascending Dose Trial of FABP5 Inhibitor to Read Out Soon

Research Report
  ()
Meanwhile, a representative from the company advancing the small molecule in the clinic is slated to speak about it at a conference this week, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Showing Results: 1 to 25 of 37 Next